Mary Hu

Company: Miracogen
Job title: Chief Executive Officer
Bio:
Dr. Mary Chaohong Hu is currently CEO of Shanghai Miracogen Inc. developing antibody drug conjugates for cancer therapeutics. She received her BS in Biochemistry from Wuhan University and Ph.D. in Molecular Biology from the Institute of Biophysics, Chinese Academy of Sciences in Beijing, China. She completed her postdoctoral training at the University of Washington, Seattle, Washington.
She has over 17 years of experience working in the biopharmaceutical/ biotech industry in the US. Before moving back to China, she was Director of Bioassay Development and Process Analytics at Seattle Genetics for development of monoclonal antibodies and antibody-drug conjugates. Prior to joining Seattle Genetics, she was Director of Molecular Biology and Clinical Immunology at GSK /ID Biomedical Corporation and was responsible for preclinical and clinical development of infectious disease vaccines.
Seminars:
Clinical Trial Update of MRG002 2:30 pm
Examine the ADC landscape in China Review preclinical findings of MRG002 Assess preliminary clinical results of MRG002Read more
day: Day Two